Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) had its target price increased by Jefferies Group LLC from $13.00 to $18.00 in a research note released on Monday morning. They currently have a buy rating on the biotechnology company’s stock. Jefferies Group also issued estimates for Spectrum Pharmaceuticals’ Q3 2017 earnings at ($0.19) EPS, Q4 2017 earnings at ($0.22) EPS, FY2017 earnings at ($0.96) EPS, FY2018 earnings at ($0.76) EPS, FY2020 earnings at $0.28 EPS and FY2021 earnings at $1.16 EPS.
Several other equities analysts have also commented on SPPI. Zacks Investment Research raised shares of Spectrum Pharmaceuticals from a sell rating to a hold rating in a research report on Wednesday, July 5th. BidaskClub lowered shares of Spectrum Pharmaceuticals from a strong-buy rating to a buy rating in a research report on Monday, July 31st. HC Wainwright reaffirmed a buy rating and issued a $14.00 price objective on shares of Spectrum Pharmaceuticals in a research report on Wednesday, August 16th. Finally, ValuEngine raised shares of Spectrum Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, August 17th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus price target of $14.75.
Spectrum Pharmaceuticals (NASDAQ:SPPI) last announced its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.26) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.01. The firm had revenue of $34.30 million during the quarter, compared to analyst estimates of $30.50 million. Spectrum Pharmaceuticals had a negative net margin of 59.33% and a negative return on equity of 30.95%. Spectrum Pharmaceuticals’s revenue was up 1.0% on a year-over-year basis. During the same period last year, the firm posted ($0.35) EPS.
WARNING: “Jefferies Group LLC Raises Spectrum Pharmaceuticals, Inc. (SPPI) Price Target to $18.00” was first reported by BBNS and is the sole property of of BBNS. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://baseballnewssource.com/markets/jefferies-group-llc-raises-spectrum-pharmaceuticals-inc-sppi-price-target-to-18-00/1704316.html.
Several institutional investors have recently made changes to their positions in SPPI. Vanguard Group Inc. raised its position in shares of Spectrum Pharmaceuticals by 13.8% in the 1st quarter. Vanguard Group Inc. now owns 7,208,723 shares of the biotechnology company’s stock valued at $46,858,000 after purchasing an additional 874,871 shares during the last quarter. State Street Corp increased its holdings in Spectrum Pharmaceuticals by 45.3% in the 1st quarter. State Street Corp now owns 2,353,958 shares of the biotechnology company’s stock worth $15,305,000 after buying an additional 733,651 shares during the period. Renaissance Technologies LLC increased its holdings in Spectrum Pharmaceuticals by 9.7% in the 1st quarter. Renaissance Technologies LLC now owns 5,679,800 shares of the biotechnology company’s stock worth $36,919,000 after buying an additional 502,488 shares during the period. Dimensional Fund Advisors LP increased its holdings in Spectrum Pharmaceuticals by 21.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,674,679 shares of the biotechnology company’s stock worth $19,926,000 after buying an additional 463,434 shares during the period. Finally, Kennedy Capital Management Inc. acquired a new position in Spectrum Pharmaceuticals in the 1st quarter worth approximately $2,054,000. 66.09% of the stock is owned by hedge funds and other institutional investors.
Spectrum Pharmaceuticals Company Profile
Spectrum Pharmaceuticals, Inc is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin’s lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM).
Receive News & Ratings for Spectrum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectrum Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.